ABOUT

Since AVVCC24, the global vaccine landscape has shifted rapidly, with funding cuts, rising misinformation and declining immunisation rates. Stronger alignment across government, industry, academia and public health is essential to reinforce the value of vaccines.

Australia is advancing infectious disease control through a new national Centre for Disease Control from January 2026 and major reforms including the National Immunisation Strategy, HTA review, Strategic Review of R&D and the forthcoming 10 Year National Health and Medical Research Strategy. In July 2025, Biointelect was awarded an MRFF BioMedTech Incubator grant to establish Biointelect Venturer, strengthening national vaccine innovation.

AVVCC26 brings these priorities together, providing a critical platform for collaboration and reinforcing Australia’s leadership in the global vaccine value chain.

AVVCC26 focuses on strengthening public private partnerships across the vaccine value chain.

Bringing together more than 600 members of the Australian Vaccine Value Chain Community, the conference will foster collaboration, respond to the evolving geopolitical landscape and support Australia’s national and regional health goals.

The program will highlight key initiatives including the Australian Centre for Disease Control, the National Health and Medical Research Strategy and the National Immunisation Strategy, while addressing vaccine hesitancy, equity of access, and the role of funding, policy and regulation in enabling innovation.

Building on AVVCC24, outcomes will be captured in the AVVCC26 Conference Outcomes Report to drive tangible progress across the Australian vaccine ecosystem.

Specifications

This bi-annual event will be hosted in NSW with the following specifications:

  • 200+ key stakeholders and decision makers from across Australia

  • Open meeting with networking events and sponsorship opportunities

  • Program committee representing public and private sectors, committed to diversity, equity and inclusion

  • Strong governance ensuring independence, balanced input and transparent conflict management

  • Publication of a Conference Outcomes Report provided to all participants

  • A strengthened vaccine community advancing public private collaboration and national public health goals.

Major Themes

OVERALL THEME: Enhancing public private partnerships across the vaccine value chain

Five major plenary sessions will include panel discussions on the key issues and selected abstract presentations that demonstrate the need for public-private value chain partnerships or exemplars:

Abstracts are encouraged that demonstrate partnerships from discovery to community and showcase diverse opportunities for collaboration across the value chain.